Study Develops Inverse Agonist for MRGPRX4 to Address Chronic Itch in Liver and Kidney Diseases

A recent study has identified a potential therapeutic approach for addressing chronic itch associated with liver and kidney diseases, particularly cholestatic and uremic disorders. Researchers have developed an inverse agonist targeting the MRGPRX4 receptor, which is implicated in cholestatic itch. The findings, published in *Nature Chemical Biology*, highlight a promising avenue for alleviating one of the most challenging symptoms faced by patients with these conditions.

Chronic itch significantly impacts the quality of life for individuals suffering from liver and kidney diseases, yet effective treatments remain scarce. The study focused on MRGPRX4, a receptor linked to itch signaling pathways in cholestatic disorders. By designing an inverse agonist that modulates this receptor’s activity, researchers demonstrated its potential to reduce itch symptoms. This discovery provides insight into the underlying mechanisms of cholestatic itch and offers hope for developing targeted therapies to address this debilitating condition.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 9, 2026

Author

GOAI